"MERIDEN Conn. June   PRNewswire  Protein Sciences Corporation http announced the publication of clinical trial results comparing Flublok Quadrivalent  the quadrivalent version of Flublok influenza vaccine http  to a traditional eggbased quadrivalent inactivated vaccine. The data published in the June nd issue http_home of the New England Journal of Medicine showed that Flublok Quadrivalent provided significantly improved protection against laboratory confirmed influenza illness in older adults.  Protein Sciences Corporation is saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals PRNewsFotoProtein Sciences Corporation  The publication notes that approximately  people aged  and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine. People who were given Flublok Quadrivalent were over  less likely to develop cultureconfirmed influenza.  This data satisfies both prespecified criteria for noninferiority and superiority of Flublok over the traditional eggbased quadrivalent inactivated vaccine.  Flublok Quadrivalent was approved by the FDA in October  and will be available nationwide in prefilled syringes for the upcoming flu season.  This study shows that Flublok Quadrivalent produced with modern recombinant technology can provide better protection against confirmed influenzalike illness among older adults than standarddose quadrivalent influenza vaccine produced with traditional technology said Lisa Dunkle MD Chief Medical Officer of Protein Sciences. We demonstrated statistically significantly better protection by Flublok based on considerably fewer people contracting the flu after vaccination with Flublok Quadrivalent. Today we announce that these peerreviewed results have been published in the highly respected New England Journal of Medicine. Furthermore physicians are eligible for up to  hour AMA PRA category  CME credit for reading the article. Clearly Flublok represents a major step forward in combating influenza on a global scale. Flublok is the only flu vaccine made without the use of eggs and therefore is not subject to the mutations that are sometimes introduced into the vaccine during the process of egg adaptation that can cause the traditional vaccines to be ineffective see Skowronski et al.  PLOS ONE  e httpjournals.plos.orgplosonearticleid.journal.pone.. Flublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza especially HN in the Flublok Quadrivalent study. Furthermore Flublok Quadrivalent is the first and only high antigencontent quadrivalent flu vaccine that with its high efficacy makes it ideal for older adults and those with a compromised immune system.  Flublok is highly purified and does not contain influenza virus antibiotics formaldehyde preservatives egg protein latex gluten or gelatin unlike other flu vaccines.  Flublok Quadrivalent is FDA approved for adults  and older. For more information about Flublok please visit  http  About Protein Sciences  Protein Sciences is a world leader in vaccine development and protein production.  Our mission is our inspiration to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals.      About Flublok  Flublok the worlds first recombinant proteinbased vaccine for the prevention of seasonal influenza disease is approved for all adults over  years. FDA approved the quadrivalent formulation Flublok Quadrivalent in October  that will be commercially available for everyone over  years for the  influenza season.  Flublok is the only flu vaccine made in a  eggfree system using modern cell culture technology making it unnecessary to use an infectious influenza virus antibiotics or harsh chemicals e.g. formaldehyde in manufacturing.  Flublok is highly purified and does not contain any preservatives e.g. thimerosal  a form of mercury egg proteins gelatin or latex.  In addition Flublok contains three times more antigen than traditional flu vaccines xmcg hemagglutinin protein versus xmcg hemagglutinin protein.  In a  postmarketing study of  adults  years and older people who received Flublok were over  less likely to develop cell culture confirmed influenza than people who received a traditional flu vaccine.  Flublok is an exact copy of the influenza virus coat protein and is not subject to the eggadapted mutations associated with low vaccine effectiveness see Skowronski et al.  PLOS ONE  e http  Healthcare professionals in the U.S. wishing to order Flublok should contact one of the following distributors  Protein Sciences Corporation   https_flublokorderformupdated.pdf   FFF Enterprises   http   Cardinal Health  http   McKesson MCKFLU mms.mckesson.com httpsmms.mckesson.comindex.mck   Moore Medical   http   Henry Schein   http Learn more at  http and  http Flublok Safety Information  Flublok is approved for people  and older to prevent influenza disease.  The most common side effect from Flublok is pain at the site of injection. Headache fatigue or muscle ache may occur.  Tell the doctor if you have ever experienced GuillainBarr syndrome severe muscle weakness or have had a severe allergic reaction to any component of Flublok vaccine. Vaccination with Flublok may not protect all individuals. Please see the complete Package Insert available at  http or call  for more information. SOURCE Protein Sciences Corporation Related Links http"